comprehensive -WSS

comprehensive

author：fashion 2025-09-29 21:28:11 - browse：1544

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： First Opinion on colorectal cancer screening: letter and response

leisure time

entertainment

WSS

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Republican states more likely to report Covid vaccine side effects

Drug cartel violence flares in western Mexico after vigilante leader's killing

First Opinion on colorectal cancer screening: letter and response

Being 'nonadherent' patient made me a more empathetic doctor

Trial using CRISPR to edit HIV out of cells disappoints

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Scientific mystery highlights the blind spots in genomics databases

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth, in a surprise, takes aim at Steward’s physician group

In Memoriam: Notable people who died in 2023

Covid silver lining: Unprecedented look at human immune system

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Novavax promises a turnaround & Lilly roils the obesity market

First Opinion on colorectal cancer screening: letter and response

hotspot

Dexcom's push to bring CGM to type 2 diabetes patients

First Opinion on colorectal cancer screening: letter and response

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Hundreds died while taking an arthritis drug, but nobody alerted patients

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Wikipedia

leisure time

entertainment

focus